UCB (WBO:UCB) Cash Payments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:UCB UCB SA WBO:UCB
90 GF Score
Price €211.40
GF Value €253.63
Valuation Modestly Undervalued
View Full Analysis

What is UCB Cash Payments?

Cash Payments only applicable to companies reporting Cash Flow from Operations in direct method.

WBO:UCB
90GF Score
UCB SA WBO:UCB
Cash Payments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is UCB (WBO:UCB) Overvalued in 2026?

Based on GuruFocus' analysis, UCB stock appears to be undervalued. The current stock price of €211.40 is trading 16.7% below its estimated GF Value™ of €253.63. GuruFocus considers UCB to be Modestly Undervalued.

Key valuation signals for WBO:UCB:

  • Cash Payments:
  • GF Value™: €253.63 vs. price of €211.40 (16.7% below fair value)
  • GF Score™: 90/100

No single metric tells the full story. See the WBO:UCB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UCB Business Description

Address Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB SA is a Belgian biopharmaceutical company that discovers, develops, and commercializes therapies for severe diseases in neurology and immunology. Its product portfolio includes treatments for epilepsy such as Vimpat, Briviact, and Nayzilam; immunology drugs including Cimzia and Bimzelx; and therapies for other neurological and rare conditions such as Neupro, Fintepla, and Evenity. The company also markets products for rare mitochondrial disease. UCB sells primarily through its own affiliates and partnerships to hospitals, specialist physicians, and pharmacies across Europe, the United States, and major international markets including Japan and emerging regions. Revenue is generated mainly from product sales, supplemented by collaboration and licensing agreements with other pharmaceutical companies. Research and development is concentrated on central nervous system disorders and immunology, with manufacturing and research sites in Belgium, the United Kingdom, Germany, and other countries.
90GF Score

Get the complete analysis for WBO:UCB

Cash Payments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€211.40
Price
€253.63
GF Value